Navigation Links
Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
Date:7/8/2008

PALO ALTO, Calif., July 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK), today announced the publication of research in Bioorganic & Medicinal Chemistry Letters describing a novel class of small molecule compounds that could potentially lead to a new treatment for diabetes. These unique compounds are the result of an extensive medicinal chemistry effort at Telik to optimize the original lead structure identified through the application of Telik's TRAP(R) technology.

The compounds developed activate the insulin receptor and may have the potential to be an orally administered treatment for diabetes. Such small molecules have been actively sought after since the discovery of insulin in the 1920s by Banting and Best, and could represent a completely different approach to the treatment of Type 1 and Type 2 diabetes. Telik's publication, Robinson, L. et al., "5-Substituted isophthalamides as insulin receptor sensitizers," Bioorg. Med. Chem. Lett., 18: 3492 (2008), describes a series of compounds that are capable of activating the insulin receptor and were also shown to increase glucose transport into adipocytes.

"Telik's drug development focus does not include diabetes and other metabolic diseases," said Marc Steuer, Senior Vice President, Business Development. "It is our intention, therefore, to seek a licensee with the requisite development skills and expertise in this therapeutic area."

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.

This press release contains "forward-looking" statements, including statements regarding the potential capabilities and qualities of the small molecules described above. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended March 31, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
2. Telik Announces First Quarter 2008 Financial Results
3. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
4. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
5. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Year-End Financial Release, Conference Call and Webcast
7. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
8. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
11. Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
Breaking Biology Technology:
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
Breaking Biology News(10 mins):